Blood filtering for shock after heart attack
Part of Heart & circulation clinical trials.
This trial tests a new blood-filtering device called Efferon CT for people with cardiogenic shock after a heart attack. The device aims to help your body recover by cleaning harmful substances from your blood, and you might join if you are diagnosed early and don't have other serious health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were just diagnosed with cardiogenic shock (very low blood pressure) after a heart attack, and it's been less than 4 hours.
- Your shock is at a moderate stage (B or C on the SCAI scale) – not too mild or too severe.
- Your overall health is good enough that you can stay on the Efferon CT blood-filtering device for at least 4 hours.
- Your SOFA score (measure of organ function) is 12 or lower, meaning your organs are not failing badly.
- You do not have certain conditions like broken-heart syndrome, recent heart attack, severe kidney disease on dialysis, or cancer/autoimmune treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called CRP apheresis, which filters a protein that causes inflammation from your blood during a heart attack complicated by cardiogenic shock. The goal is to reduce inflammation and improve recovery in people undergoing a heart procedure to open blocked arteries.
This trial tests a new kind of cell therapy made from donor cells that aims to reduce inflammation and help the heart recover after a severe heart attack. It's designed for people who are in cardiogenic shock (when the heart can't pump enough blood) despite having had emergency procedures like stents or bypass surgery.
This trial tests a new heart-assist device designed to help patients whose hearts are too weak to pump blood on their own after heart surgery. The device is placed through a catheter (thin tube) and aims to improve blood flow and survival in people who don't respond to standard medications.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This registry tracks patients experiencing cardiogenic shock—a serious condition where the heart suddenly cannot pump enough blood to the body. Researchers collect information about patient outcomes and treatments to better understand what helps people recover.
This study tests a device that helps the heart pump blood when it is too weak to do so, even with medicine, after surgery, or while waiting for a transplant. It aims to see if it's safe and works well.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.